Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
-10 to -25°C
SMILES string
[S](=O)(=O)(CCCN1CCN(CC1)C(=O)N2[C@]([C@](N=C2c5c(cc(cc5)C(C)(C)C)OCC)(C)c4ccc(cc4)Cl)(C)c3ccc(cc3)Cl)C
InChI
1S/C38H48Cl2N4O4S/c1-8-48-33-26-29(36(2,3)4)14-19-32(33)34-41-37(5,27-10-15-30(39)16-11-27)38(6,28-12-17-31(40)18-13-28)44(34)35(45)43-23-21-42(22-24-43)20-9-25-49(7,46)47/h10-19,26H,8-9,20-25H2,1-7H3/t37-,38+/m0/s1
InChI key
QBGKPEROWUKSBK-QPPIDDCLSA-N
Biochem/physiol Actions
Orally active, potent and selective MDM2 inhibitor with anti-cancer efficacy in cultures and in vivo by induces p53-dependent cell cycle arrest and apoptosis.
RG7112 is an orally active, potent and selective MDM2 inhibitor that binds and blocks p53-binding site (IC50 = 18 nM), thereby induces p53-dependent cell cycle arrest and apoptosis (av GI50 by MTT assays = 0.4 μM/wt 53 vs 33.4 μM/mutant p53) by stabilizing cellular p53. When administered in vivo, RG7112 is efficacious against the growth of tumor xenografts in mice (SJSA-1, SJSA-1luc2, and MHM; 25-200 mg/kg via daily p.o.).
RG7112 is an orally active, potent and selective MDM2 inhibitor that binds and blocks p53-binding site (IC50 = 18 nM), thereby induces p53-dependent cell cycle arrest and apoptosis (av GI50 by MTT assays = 0.4 μM/wt 53 vs 33.4 μM/mutant p53) by stabilizing cellular p53. When administered in vivo, RG7112 is efficacious against the growth of tumor xenografts in mice (SJSA-1, SJSA-1luc2, and MHM; 25-200 mg/kg via daily p.o.).
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable